For infants on phosphorous, calcium, vitamin D, or calcitriol treatments, the goals are to normalize PTH levels, monitor for hypercalciuria, and to normalize phosphorus levels by limiting urinary phosphorus wasting, as evidenced by increases in TRP. The gene discussed is PTH; the disease is Hypercalciuria.